AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:18 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:18 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs
by Zacks Equity Research
PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs are included in this Analyst Blog.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $137.82, marking a -0.59% move from the previous day.
Top Analyst Reports for PepsiCo, AbbVie & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), AbbVie Inc. (ABBV) and Honeywell International Inc. (HON).
Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT
by Zacks Equity Research
Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.
AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) CAR T cell therapy has achieved an overall response rate of 83% in patients with Waldenstrom macroglobulinemia.
Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion
by Zacks Equity Research
Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $137.73, moving -0.33% from the previous trading session.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
AstraZeneca (AZN) Discontinues Brazikumab Development
by Zacks Equity Research
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
by Zacks Equity Research
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Top Research Reports for AbbVie, Intel & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).
Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
by Zacks Equity Research
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP